Advertisement
Document › Details
Sanofi S.A.. (6/7/19). "Press Release: Paul Hudson to Succeed Olivier Brandicourt as Chief Executive Officer". Paris.
At its meeting on June 6th of 2019, Sanofi's Board of Directors unanimously appointed Paul Hudson as Chief Executive Officer of the Group, to succeed Olivier Brandicourt who has decided to retire.
The Board of Directors would like to thank Olivier Brandicourt for the energy with which he has steered the Group through a complex period and for his decisive contribution to the company's return to growth. Thanks to the actions undertaken during his term of office, Sanofi is able to accelerate its growth, and has powerful assets to regain the position it needs to occupy.
As of September 1, 2019, he will be replaced by Paul Hudson, who most recently was Chief Executive Officer of Novartis Pharmaceuticals and Member of the Executive Committee of Novartis.
Paul Hudson, 51 years old, is a seasoned leader with a strong international experience, particularly in the United States, Japan and Europe. He spent his 28-years career with major pharmaceutical companies such as Schering Plough, Astra Zeneca and Novartis. Throughout his various management positions, he has proven his strategic vision, his strong leadership and his ability to achieve the greatest challenges, particularly in terms of innovation and digital transformation. Mr. Hudson has a very robust track record in successful major product launches. Paul Hudson will move to Paris.
Serge Weinberg, Chairman of the Board of Directors of Sanofi, said: "We are very pleased that Paul Hudson has agreed to join Sanofi. His skills and experience give him all the assets he needs to accelerate growth and lead the Group's adaptation to new strategic challenges, particularly in the areas of Research and Development and digital. His human values will enable him to mobilize all the energies and increase the agility, that a group such as Sanofi needs, to face the new challenges of our industry and the changes in healthcare systems around the world".
About Sanofi
Sanofi is dedicated to supporting people through their health challenges. We are a global biopharmaceutical company focused on human health. We prevent illness with vaccines, provide innovative treatments to fight pain and ease suffering. We stand by the few who suffer from rare diseases and the millions with long-term chronic conditions.
With more than 100,000 people in 100 countries, Sanofi is transforming scientific innovation into healthcare solutions around the globe.
Sanofi, Empowering Life
Head of Communication, Sanofi
Josep Catlla
Tél.: +33 (0) 7 89 07 80 33
Josep.catlla@sanofi.com
Image7
Anne Méaux
Tél.: +33 (0) 6 89 87 61 76
ameaux@image7.fr
Image7
Laurence Heilbronn
Tél.: +33 (0) 6 89 87 61 37
lheilbronn@image7.fr
About Sanofi
Sanofi is dedicated to supporting people through their health challenges. We are a global biopharmaceutical company focused on human health. We prevent illness with vaccines, provide innovative treatments to fight pain and ease suffering. We stand by the few who suffer from rare
Record changed: 2023-06-05 |
Advertisement
More documents for Sanofi (Group) [since May 2011]
- [1] MeiraGTx Holdings plc. (10/30/23). "Press Release: MeiraGTx Announces $30 Million Strategic Investment from Sanofi; Company Pursuing Multiple Additional Strategic Opportunities". London & New York, NY....
- [2] Glycomine, Inc.. (7/11/22). "Press Release: Glycomine Appoints Steven Axon as CEO and Adds Two New Board Directors". San Carlos, CA....
- [3] Exscientia plc. (1/7/22). "Press Release: Exscientia and Sanofi Establish Strategic Research Collaboration to Develop AI-driven Pipeline of Precision-Engineered Medicines". Paris, Oxford & Boston, MA....
- [4] MoonLake Immunotherapeutics AG. (8/10/21). "Press Release: MoonLake Immunotherapeutics Appoints Former Kymab CEO Simon Sturge as Chairman and Spike Loy to the Board of Directors". Zug....
- [5] Sanofi S.A.. (1/11/21). "Press Release: Sanofi to Acquire Kymab, Adding KY1005 to Its Pipeline, a Human Monoclonal Antibody Targeting Key Immune System Regulator OX40L". Paris & Cambridge....
- [6] GlaxoSmithKline plc. (7/31/20). "Press Release: Sanofi and GSK Selected for Operation Warp Speed to Supply United States Government with 100 Million Doses of COVID-19 vaccine". London & Paris....
- [7] GlaxoSmithKline plc. (7/31/20). "Press Release: Sanofi and GSK in Advanced Discussions with European Union to Supply up to 300 Million Doses of COVID-19 Vaccine". London & Paris....
- [8] Oxford Biomedica plc. (6/9/20). "Press Release: Oxford Biomedica Provides Update on Ophthalmology Programmes Out-licensed to Sanofi". Oxford....
- [9] Kymab Group Ltd.. (4/14/20). "Press Release: US Patent Trial and Appeal Board Rejects Requests Filed by Regeneron. USPTO Upholds 4 Kymab Patents Covering Human Antibodies and Platforms". Cambridge....
- [10] GlaxoSmithKline plc. (4/14/20). "Press Release: Sanofi and GSK to Join Forces in Unprecedented Vaccine Collaboration to Fight COVID-19". London....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)
Advertisement
» top